These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21322823)

  • 1. [Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].
    Kolykhalov IV; Rassadina GA; Gavrilova SI; Gerasimov NP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):33-8. PubMed ID: 21322823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Suppl 1):33-8. PubMed ID: 20559265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.
    Grossberg GT
    Drugs Aging; 2008; 25(7):573-84. PubMed ID: 18582146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.
    Gauthier S; Juby A; Rehel B; Schecter R
    Int J Clin Pract; 2007 Jun; 61(6):886-95. PubMed ID: 17504350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The treatment of Alzheimer's disease in patients with comorbid somatic pathology].
    Selezneva ND; Gavrilova SI; Kalyn IaB; Kolykhalov IV; Fedorova IaB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):35-42. PubMed ID: 18833116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.
    Mets T; Vandewoude M; Jacquy J; Deblander A; MacDonald K; Sloesen A; Abraham I;
    Curr Med Res Opin; 2007 Oct; 23(10):2485-501. PubMed ID: 17784995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of the open multicenter prospective study of safety and tolerability of rivastigmine (exelon) in different titration regimes in mild and moderate Alzheimer's disease].
    Litvinenko IV; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):29-35. PubMed ID: 19672235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
    Alva G; Grossberg GT; Schmitt FA; Meng X; Olin JT
    Int J Geriatr Psychiatry; 2011 Apr; 26(4):356-63. PubMed ID: 21312297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
    Finkel SI
    Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
    Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
    Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study].
    Cruz Jentoft AJ; Hernández B
    Neurologia; 2014; 29(1):1-10. PubMed ID: 23582372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
    Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
    Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.